Scilex announced that the State of Tennessee added ZTlido as a preferred agent to the Medicaid Preferred Drug List effective as of October 1, 2023.1 This change has the potential to improve access to ZTlido for all eligible patients which includes approximately 1,500,000 adult lives between the ages of 19 to 64.1 “As we continue our commitment to improving access for ZTlido(R), the addition of ZTlido to the Medicaid Preferred Drug List of the State of Tennessee is another important step in the expansion of the use of ZTlido throughout the U.S. Importantly, our diversified portfolio of leading pain management products allows us to offer patients complementary and standalone non-opioid pain management solutions,” said Jaisim Shah, Chief Executive Officer and President of Scilex.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SCLX:
- Scilex reports November ZTildo gross sales $14M-$15M
- Scilex announces successful FDA audit of enhanced ZTlido manufacturing facility
- Scilex Holding Company announces successful FDA audit of enhanced ZTlido® manufacturing facility in Japan
- Scilex announces pharmacy initiative to stock ELYXYB in over 500 stores
- Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S.